IO	Immuno-oncology
ICI	Immune checkpoint inhibitor
IgG1	Immunoglobulin G
CTLA-4	Cytotoxic T-lymphocyte antigen-4
TME	Tumor microenvironment
OV	Oncolytic virus
Ab	Antibody
PD-1	Programmed death 1
PD-L1	Programmed death-ligand 1
irAE	Immune-related adverse events
TIL	Tumor infiltrating lymphocyte
HMGB-1	High-mobility group protein box 1
TIM-3	T cell immunoglobulin and mucin domain 3
APC	Antigen-presenting cells
IFN- γ	Interferon gamma
IL-4	Interleukin
DC	Dendritic cells
LAG-3	Lymphocyte-activation gene 3
MHC	Major histocompatibility complex
Treg	Regulatory T cells
RGBM	Recurrent glioblastoma
Gal-9	Galectin-9
CEACAM1	Carcinoembryonic antigen-related cell adhesion molecule 1
PS	Phosphatidylserine
TIGIT	Tyrosine-based inhibition motif domain
VISTA	V-domain Ig suppressor of T cell activation
PAMPS	Pathogen-associated molecular patterns
TAA	Tumor-associated antigens
DAMPS	Danger-associated molecular patterns
IL-12	Interleukin 12
GM-CSF	Granulocyte-macrophage colony-stimulating factor
HSV	Herpes simplex virus
MAGE-A3	Melanoma-associated antigen 3
NY-ESO-1	New York esophageal squamous cell carcinoma 1
TNF-α	Tumor necrosis factor-alpha
IL-2	Interleukin 2
hTERT	Human telomerase reverse transcriptase
MART	T cell-recognized melanoma antigen
DLT	Dose-limiting toxicity
ICAM	Intercellular adhesion molecule 1
DAF	Decay-accelerating factor
NIS	Sodium iodide symporter
NSCLS	Non-small-cell lung carcinoma
AML	Acute myeloid leukemia
TNBC	Triple negative breast cancer
IRES	Internal ribosome entry site
NDV	Newcastle disease virus
ICOS	Inducible co-stimulator